WNK2 and cancer: In the Mitogen-Activated Protein Kinase (MAPK) signaling pathway, MAPK inhibitors are efficient blockers to reduce pro-inflammatory cytokines and enhance the anti-cancer effect, particularly on human pancreatic cancer cells [53,54].